» Articles » PMID: 28587956

Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development Via STAT6 Activation in an Atopic Condition Melanoma Model

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2017 Jun 8
PMID 28587956
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A protective effect of allergy for cancer has been suggested, but the results are somewhat conflicting, and the mechanism remains elusive. Interleukin-4 (IL-4) signaling has been identified as a potentially important pathway in the development of allergies and the suppression of cancer development. To evaluate the allergy responses in IL-4-mediated tumor development, we compared the growth of B16F10 melanoma cells in 4% phthalic anhydride (PA)-treated IL-4/Luc/CNS-1 transgenic mice (IL-4 mice) and acetone-olive oil (AOO)-treated IL-4 mice as a control for 3 weeks. Much higher allergic responses and natural killer (NK) and STAT6 activation were found in PA-treated IL-4 mice compared with AOO-treated IL-4 control mice. Tumor volume and weight showed an inverse association with the higher allergic response and were significantly reduced in the PA-treated IL-4 mice when compared with those of AOO-treated IL-4 control mice. Significantly higher activation of STAT6, as well as IL-4 and NK cell activation, was found in the tumor tissues of PA-treated IL-4 mice. Infiltration of immune cells and cytokine levels were also higher in the tumor tissues of PA-treated IL-4 mice. We further found that IL-4-activated NK-92MI cells showed increased anticancer effects in human melanoma cells. Overall, these results showed that allergy responses further accelerated the IL-4-induced inhibition of tumor development through the activation of STAT6 pathways.

Citing Articles

Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors .

Nguyen V, Kim H, Choi Y, Park J, Choi E Drug Deliv. 2022; 29(1):2621-2631.

PMID: 35941835 PMC: 9367655. DOI: 10.1080/10717544.2022.2105444.


Rapamycin Promotes ROS-Mediated Cell Death Functional Inhibition of xCT Expression in Melanoma Under γ-Irradiation.

Woo Y, Lee H, Kim J, Kang S, Moon S, Han J Front Oncol. 2021; 11:665420.

PMID: 33959512 PMC: 8093631. DOI: 10.3389/fonc.2021.665420.


JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.

Gotthardt D, Trifinopoulos J, Sexl V, Putz E Front Immunol. 2019; 10:2590.

PMID: 31781102 PMC: 6861185. DOI: 10.3389/fimmu.2019.02590.


Oxidative Stress Markers Patients with Parotid Gland Tumors: A Pilot Study.

Sowa P, Misiolek M, Pasinski B, Bartosz G, Soszynski M, Adamczyk-Sowa M Biomed Res Int. 2018; 2018:4340871.

PMID: 29651432 PMC: 5832034. DOI: 10.1155/2018/4340871.

References
1.
Simpson C, Anderson W, Helms P, Taylor M, Watson L, Prescott G . Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data. Clin Exp Allergy. 2002; 32(1):37-42. DOI: 10.1046/j.0022-0477.2001.01250.x. View

2.
Kiekens R, Thepen T, Bihari I, Knol E, van de Winkel J, Bruijnzeel-Koomen C . Expression of Fc receptors for IgG during acute and chronic cutaneous inflammation in atopic dermatitis. Br J Dermatol. 2000; 142(6):1106-13. DOI: 10.1046/j.1365-2133.2000.03534.x. View

3.
Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P . Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol. 1997; 151(3):689-96. PMC: 1857831. View

4.
Platteau C, Loose M, De Meulenaer B, Taverniers I . Detection of allergenic ingredients using real-time PCR: a case study on hazelnut (Corylus avellena) and soy (Glycine max). J Agric Food Chem. 2011; 59(20):10803-14. DOI: 10.1021/jf202110f. View

5.
Lange F, Rateitschak K, Fitzner B, Pohland R, Wolkenhauer O, Jaster R . Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach. Mol Cancer. 2011; 10(1):13. PMC: 3042009. DOI: 10.1186/1476-4598-10-13. View